

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

GENERAL DISCLOSURE PURSUANT TO RULE 13.18 OF THE LISTING RULES

This announcement is made pursuant to Rule 13.18 of the Listing Rules with respect to the Facility Letter, which contains specific performance obligations imposed on the controlling shareholders of the Company.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) (“**Listing Rules**”) with respect to a facility letter dated 24 November 2009 (the “**Facility Letter**”) and accepted by Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**”) (as borrower) on 14 December 2009, made between Hang Seng Bank Limited (“**Hang Seng Bank**”) (as lender) and the Company, which contains specific performance obligations imposed on the controlling shareholders of the Company.

The Facility Letter is for a term loan facility of HK\$50,000,000, the final maturity date of which shall be the date falling 3 years after the date of drawdown, and the drawdown date shall be within 5 months from the date of the Facility Letter.

The Facility Letter provides that from the date of the Facility Letter and, so long as the indebtedness under the Facility Letter remain outstanding, the Company will procure that: (1) Prime United Industries Limited (“**Prime United**”) and China Pharmaceutical Company Limited (“**CPCL**”) shall in aggregate maintain not less than 51% beneficial ownership of the shareholding of the Company; and (2) Mr. Wu Qin and Mr. Qu Jiguang shall remain as directors of the Company.

Any breach of the above specific performance obligations would constitute a default under the Facility Letter. Such default would allow Hang Seng Bank to declare (i) the facility terminated and (ii) all the indebtedness under the Facility Letter become due and payable.

As at the date of this announcement, Prime United and CPCL respectively own 30.69% and 27.33% of equity interest of the Company. Mr. Wu Qin holds 2.43% of beneficial interest of equity interest of Prime United; and holds jointly, with the executive Directors, namely Mr. Huang Chao and Mr. Xie Yunfeng, an aggregate of 84.73% of equity interest of Prime United, on trust for 4,479 individuals, who are present and former employees or their respective estates of Xi'an Lijun Pharmaceutical Co., Ltd. (西安利君製藥有限責任公司) ("**Xi'an Lijun**") and Rejoy Group Limited Liability Company (利君集團有限責任公司) ("**Rejoy Group**"). Mr. Wu Qin is also a director of Prime United. Xi'an Lijun is a company established in the PRC with limited liability and wholly-owned by the Company. Rejoy Group is a company established in the PRC with limited liability and 100% owned by State-owned Assets Supervision and Administration Commission of the People's Government of Xian. Mr. Qu Jiguang holds 72.93% of beneficial interest of equity interest of CPCL and is a director of CPCL.

This announcement is made pursuant to Rule 13.18 of the Listing Rules. In accordance with the requirements thereunder, disclosure will be included in the interim and annual reports of the Company for so long as the above specific performance obligations continue to exist.

By order of the Board
Sze Wing Kin, Pierre
Company Secretary

Hong Kong, 14 December 2009

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Huang Chao, Mr. Xie Yunfeng, Ms. Sun Xinglai, Mr. Wang Xianjun, Mr. Duan Wei, Ms. Zhang Guifu, Mr. Bao Leyuan and Ms. Gao Shuping as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.